阿斯利康

1. 日本卫生、劳动与福利部（MHLW）批准 Bevespi Aerosphere 用于治疗慢性阻塞性肺病（COPD）患者。
   http://tinyurl.com/y6zgunue



2. Lynparza 在日本获批作为 BRCA 突变晚期卵巢癌的一线维持疗法。
   http://tinyurl.com/y3597rca



百时美施贵宝

1. 百时美施贵宝今天宣布，Catalent 同意收购其在意大利 Anagni 的口服固体、生物制剂和无菌产品制造和包装设施。
   http://tinyurl.com/y2cm4tx4



Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines

Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms

WEDNESDAY, JUNE 19, 2019 6:59 AM EDT

NEW YORK & SOMERSET, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions.

吉利德

1. Gilead 和 Nurix Therapeutics 建立战略合作，开发癌症和其他疾病的新疗法,将利用 Nurix 的专有药物开发平台识别消除特定靶标的新药物。
   http://t.cn/AiNgRJqa

June 19, 2019

Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

-- Collaboration will Leverage Nurix's Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets --

FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Jun. 19, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body's natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.

百健

1. BIOGEN 将于 2019 年 7 月 23 日（星期二）公布 2019 年第二季度报告财务业绩。 http://t.cn/AiNgEU3N

BIOGEN TO REPORT SECOND QUARTER 2019 FINANCIAL RESULTS JULY 23, 2019

June 19, 2019 at 4:05 PM EDT

Cambridge, MA, -- Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2019 financial results Tuesday, July 23, 2019, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET. To access the live webcast, please go to the investors section of Biogen's website at http://investors.biogen.com/. Following the live webcast, an archived version of the call will be available on the website.